Traumatic Brain Injury Market
- Traumatic Brain Injury (TBI) market is anticipated to grow in the near future, mainly attributed to factors such as the increasing incidence of TBI, advancements in diagnostic technologies, the emergence of novel therapies, and increasing injuries among the general population. Additionally, demographic factors such as an aging population and regional variations in disease burden are also determining factors impacting the overall market growth.
- To drive the Traumatic Brain Injury (TBI) Market in the future years, several companies such as veriNOS Pharmaceutical, SanBio, BioVie, Hope Biosciences, Cellvataion, NeuroTrauma Sciences, LLC., and others are developing their assets in the mid-late stage of development. With the expected approval of these therapies during the forecast period (2023–2032), the overall therapeutic market of Traumatic Brain Injury (TBI) is likely to rise at a significant CAGR.
DelveInsight’s report titled “Traumatic Brain Injury (TBI) Market Insights, Epidemiology, and Market Forecast – 2032” provides a comprehensive analysis of Traumatic Brain Injury (TBI). The report includes a detailed examination of the historical and projected epidemiology data, including incident cases of Traumatic Brain Injury (TBI), segmented by gender, age, and severity. The market report on Traumatic Brain Injury (TBI) provides comprehensive insights into different aspects concerning the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and future developments in the market across the seven major markets, namely the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2019 to 2032.
The report examines present treatment practices and algorithms for Traumatic Brain Injury (TBI) and explores unmet medical needs to assess the overall potential of the market and identify business opportunities.
The US, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan
Traumatic Brain Injury Epidemiology
Traumatic Brain Injury Market
Traumatic Brain Injury Market Analysis
Traumatic Brain Injury Market Players
Traumatic Brain Injury Future Opportunity
With no approved therapies in the market, Pharma companies can cater to the existing unmet needs of novel therapies and crack the code for further traumatic brain injury treatment. Further, extensive R&D for studying various diagnostic techniques for detecting traumatic brain injury holds immense potential to change the treatment paradigm for severe patients.
Traumatic Brain Injury (TBI) Overview
A traumatic brain injury (TBI) is a complex and potentially serious condition that occurs when an external force, such as a blow or jolt to the head, disrupts the normal functioning of the brain. TBIs can range from mild to severe and can have a wide range of physical, cognitive, emotional, and behavioral effects. Further, the risk of TBI among males is twice the risk among females.
Traumatic Brain Injury (TBI) Diagnosis and Treatment Algorithm
To diagnose traumatic brain injury, doctors assess the history of the injury, the patient’s symptoms, the physical examination, and additional tests, including neuroradiology. Many traumatic brain injury patients experience a loss of consciousness (blacking out) during their injury. Loss of consciousness most commonly lasts from seconds to minutes, but severe traumatic brain injury (may last for days (coma) and may persist indefinitely in the most severe cases. Patients with mild traumatic brain injury (concussion) may not experience any loss of consciousness. Most traumatic brain injury patients have some degree of amnesia (memory loss) for the minutes to hours or longer surrounding their injury.
Treating traumatic brain injury (TBI) varies depending on the severity of the injury and the specific symptoms and complications that arise. The primary goal of treatment is to prevent any secondary injury to the brain. Patients with mild traumatic injuries do not require specific treatment other than OTC pain relievers. However, for the treatment of moderate to severe traumatic brain injury, several medications are used, including diuretics, anti-seizure/anticonvulsant drugs, and anti-depressants. In some cases of moderate to severe traumatic brain injury, surgery and rehabilitation are also required.
Traumatic Brain Injury (TBI) Epidemiology
The epidemiology section of the report on traumatic brain injury (TBI) analyzes the historical and current patient pool of traumatic brain injury (TBI) and provides projected trends for the 7MM. It aims to understand the underlying factors contributing to the current and projected trends by considering various studies and insights from key opinion leaders. This section of the report also presents information on the diagnosed patient pool, its trends, and the assumptions made during the analysis.
The epidemiology section on the traumatic brain injury (TBI) market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The incident patient pool, their trends, and the underlying assumptions are all included in this section of the report.
According to the Centers for Disease Control and Prevention (2016), traumatic brain injury (TBI) is a leading cause of death and disability among children and young adults in the United States. Each year, an estimated 1.5 million Americans sustain a traumatic brain injury. Further, this risk is highest among adolescents, young adults, and persons older than 75 years.
As per Dewan et al. (2018), the overall incidence of traumatic brain injury per 90,000 people was greatest in North America (1299 cases, 95% CI 650–1947) and Europe (912 cases, 95% CI 910–1013).
According to Maegele et al. (2019), as determined from cases documented in the DGU Trauma Register over the period between 2013 and 2017, the incidence of hospitalization for moderate to severe traumatic brain injury (TBI) in Germany is 9.1 per 90,000 persons per year. The overall incidence is estimated at 13.6 per 90,000 persons per year.
In 2016, according to Paget et al. (2021), the incidence rate of traumatic brain injury was 230.6/90,000 persons in France.
Traumatic Brain Injury (TBI) Market Outlook
Traumatic brain injury (TBI) is a significant health concern and a leading cause of death and disability among children and young adults. Treating traumatic brain injury is complex and carries a significant financial burden. Treatment of psychiatric symptoms following a concussion is based on individual factors and the nature and severity of symptom presentation. It may include physiotherapy, psychotherapeutic, and pharmacological treatment modalities.
Mild traumatic brain injury, also called concussion, may not require specific treatment other than the rest. However, healthcare providers recommend physical and cognitive rest to allow the brain to heal. Further, over-the-counter pain relievers may be used to manage headaches.
However, in case of moderate to severe traumatic brain injuries, emergency medical care is required that focuses on stabilizing and keeping the patient alive, ensuring the brain gets enough oxygen, controlling blood and brain pressure, and preventing further injury to the head or neck. In some cases, surgeries for removing blood clots or pools, repairing skull fracture, and relieving pressure inside the skull is needed as part of emergency care to reduce damage to the brain.
Different medication classes, including anti-anxiety, anticoagulants, anticonvulsants, anti-depressants, diuretics, stimulants, and muscle relaxants, are used to help treat symptoms of traumatic brain injury and lower the risk of associated conditions. Stimulants help improve some aspects of cognitive functions, such as alertness and attention, by increasing the levels of neurotransmitters such as norepinephrine and dopamine. Stimulants used in traumatic brain injury treatment include methylphenidate hydrochloride (RITALIN, DAYTRANA) and modafinil (PROVIGIL). Anticonvulsants like phenytoin, valproate sodium, gabapentin, and others are used. Selective serotonin reuptake inhibitors (SSRIs) increase the level of serotonin, a neurotransmitter that regulates mood. SSRIs like sertraline, citalopram, and paroxetine are administered to treat emotional disturbances that can occur after a traumatic brain injury.
Currently, there are no approved therapies for traumatic brain injury. The existing medications used for those suffering from traumatic brain injury focus on treating the symptoms and stopping the pain instead of preventing any further damage from occurring. To overcome this shortcoming of the therapeutic market and to provide better treatment options for the moderate to severe traumatic brain injury patient pool, many molecules are being explored at different levels. Various market players are developing emerging therapies that are currently under investigation.
According to DelveInsight, the Traumatic Brain Injury (TBI) market in the 7MM is expected to change significantly during the study period 2019–2032.
Traumatic Brain Injury (TBI) Drug Chapters
Emerging Traumatic Brain Injury (TBI) Drugs
The Traumatic Brain Injury (TBI) market dynamics are anticipated to undergo transformation primarily driven by the global increase in healthcare expenditure. Traumatic Brain Injury (TBI) Market players such as BioVie, Hope Biosciences, veriNOS Pharmaceutical, SanBio, Cellvataion, and others are actively involved in developing Traumatic Brain Injury (TBI) treatments.
VAS203 (ronopterin): veriNOS Pharmaceuticals
VAS203 (ronopterin) is an allosteric iNOS inhibitor that rapidly lowers excessive NO production resulting from acute iNOS activation. It does not materially affect the physiological production of NO by other constitutive enzymes, which are essential for brain function. By targeting both cerebral blood vessels and cerebral tissue in a region-specific manner, VAS203 represents a completely novel pharmacological approach to TBI that can be administrated in addition to the best standard of care. The drug has completed the Phase III NOSTRA trial in patients with moderate and severe traumatic brain injury.
SB623 (vandefitemcel): SanBio
SB623 (vandefitemcel) is a proprietary, cell-based investigational product made from modified and cultured adult bone marrow-derived mesenchymal stem cells that undergo temporary genetic modification. Implantation of SB623 cells into injured nerve tissue in the brain is expected to trigger the brain’s natural regenerative ability to recover lost motor functions. It is currently being investigated for treating chronic neurological motor deficit resulting from traumatic brain injury and ischemic stroke and has completed a Phase II trial.
Note: Detailed emerging therapies assessment will be provided in the final report...
Allosteric iNOS inhibitor
Traumatic Brain Injury (TBI) Market Segmentation
DelveInsight’s ‘Traumatic Brain Injury (TBI) Market Insights, Epidemiology, and Market Forecast – 2032’ report provides a detailed outlook of the current and future Traumatic Brain Injury (TBI) market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by individual therapies to provide a detailed view of the current and future market share of all therapies.
Traumatic Brain Injury (TBI) Market Size by Countries
The total Traumatic Brain Injury (TBI) market size is analyzed for individual countries (the United States Market, EU4 [Germany, France, Italy, and Spain] the UK market, and Japan). The United States accounted for a larger portion of the 7MM market for Traumatic Brain Injury (TBI) in 2022 due to the high incidence of the condition and the higher cost of treatments. This dominance is predicted to continue with the potential early entry of new products.
Traumatic Brain Injury (TBI) Market Size by Therapies
The traumatic Brain Injury (TBI) Market Size by Therapies is categorized into current and emerging markets for the study period 2019–2032. The emerging drug anticipated to launch during the forecast period includes VAS203 (ronopterin) and SB623 (vandefitemcel), among others.
Note: Detailed market segment assessment will be provided in the final report....
Traumatic Brain Injury (TBI) Drugs Uptake
This section focuses on the sales uptake of potential Traumatic Brain Injury (TBI) drugs that have recently launched or are anticipated to be launched in the Traumatic Brain Injury (TBI) market between 2019 and 2032. It estimates the market penetration of Traumatic Brain Injury (TBI) drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the Traumatic Brain Injury (TBI) market.
The emerging Traumatic Brain Injury (TBI) therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the Traumatic Brain Injury (TBI) market.
Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on Traumatic Brain Injury (TBI)...
Traumatic Brain Injury (TBI) Market Access and Reimbursement
DelveInsight’s ‘Traumatic Brain Injury (TBI) Market Insights, Epidemiology, and Market Forecast – 2032’ report provides a descriptive overview of the market access and reimbursement scenario of Traumatic Brain Injury (TBI).
This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.
To keep up with current Traumatic Brain Injury (TBI) market trends and fulfill gaps in secondary findings, we interview KOLs and SMEs’ working in the Traumatic Brain Injury (TBI) domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or Traumatic Brain Injury (TBI) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Traumatic Brain Injury (TBI) unmet needs.
Traumatic Brain Injury (TBI): KOL Insights
DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as the Brain Injury Association of America in the US, the National Federation of the Traumatic Brain Injury (TBI) Associations (FNATC) in Italy, Osaka University Graduate School of Medicine in Japan.
“The current medical management of TBI patients mainly includes specialized pre-hospital care, intensive clinical care, and long-term rehabilitation, but lacks clinically proven effective management with neuroprotective agents to limit secondary injury or enhance repair.”
Note: Detailed assessment of KOL Views will be provided in the full report on Traumatic Brain Injury (TBI)...
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Traumatic Brain Injury (TBI) Market using various Competitive Intelligence tools, including SWOT analysis, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Traumatic Brain Injury (TBI) Pipeline Development Activities
The Traumatic Brain Injury report provides insights into Traumatic Brain Injury Clinical Trials within Phase II and III stages. It also analyzes Traumatic Brain Injury (TBI) companies developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging Traumatic Brain Injury (TBI) therapies.
Traumatic Brain Injury (TBI) Report Insights
- Traumatic Brain Injury (TBI) Patient Population
- Traumatic Brain Injury Therapeutic Approaches
- Traumatic Brain Injury (TBI) Pipeline Analysis
- Traumatic Brain Injury (TBI) Market Size and Trends
- Traumatic Brain Injury (TBI) Market Opportunities
- Impact of Upcoming Traumatic Brain Injury Therapies
Traumatic Brain Injury (TBI) Report Key Strengths
- Ten Years Forecast
- The 7MM Coverage
- Traumatic Brain Injury (TBI) Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Traumatic Brain Injury (TBI) Market
- Traumatic Brain Injury (TBI) Drugs Uptake
Traumatic Brain Injury (TBI) Report Assessment
- Traumatic Brain Injury (TBI) Current Treatment Practices
- Traumatic Brain Injury Unmet Needs
- Traumatic Brain Injury (TBI) Pipeline Product Profiles
- Traumatic Brain Injury (TBI) Market Attractiveness
- Traumatic Brain Injury Market Drivers
- Traumatic Brain Injury Market Barriers
Key Questions Answered In The Traumatic Brain Injury Market Report
- What are the key findings of the market across the 7MM, and what country will have the largest Traumatic Brain Injury (TBI) market size during the forecast period (2023–2032)?
- At what CAGR is the Traumatic Brain Injury (TBI) market, and is epidemiology expected to grow in the 7MM during the forecast period (2023–2032)?
- How would the unmet needs impact the Traumatic Brain Injury (TBI) market dynamics and subsequently influence the analysis of related trends?
- What would be the forecasted patient pool of Traumatic Brain Injury (TBI) in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
- What are the latest advancements in novel therapies, targets, mechanisms of action, and technologies being developed to address the limitations of existing therapies for Traumatic Brain Injury (TBI)?
- How many companies are developing therapies for treating Traumatic Brain Injury (TBI)?